A systematic review pooled 32 randomised trials and 47,332 people taking tirzepatide or semaglutide for type 2 diabetes or obesity, and looked specifically at blood-pressure-related adverse events rather than at millimetres of mercury. Tirzepatide was linked to far fewer hypertension events (risk ratio 0.40, 95% CI 0.26 to 0.60) but to more than double the hypotension events (RR 2.45, 95% CI 1.35 to 4.45), rising to 2.58 at higher doses. Semaglutide sat in the middle on both counts, with no significant effect on hypertension events (RR 0.81, 95% CI 0.57 to 1.15) or hypotension events (RR 1.39, 95% CI 0.81 to 2.36).
The useful finding is not that tirzepatide lowers blood pressure - that was known - but that it lowers it enough, in enough people, to produce symptomatic events. Most patients starting tirzepatide are already on an angiotensin-converting-enzyme inhibitor or an angiotensin receptor blocker, often with a diuretic, and are simultaneously eating and drinking less. Those three things add up.
In clinic this argues for treating a tirzepatide titration the way you would treat starting a new antihypertensive. Check sitting and standing blood pressure at each dose step. Ask directly about light-headedness on standing, which patients rarely volunteer. Where blood pressure is already at or below target, plan the antihypertensive reduction in advance rather than waiting for a fall. This is more pressing in Indian practice, where lower body weight, hot weather and lower fluid intake all make volume depletion easier to reach.
- Measure sitting and standing blood pressure at every tirzepatide dose escalation, not just at baseline
- Ask specifically about dizziness on standing, early morning unsteadiness and near-faints
- Review diuretics first when blood pressure falls - they are usually the easiest agent to reduce or stop
- Reassess the antihypertensive regimen once weight loss exceeds about 10%, whichever incretin is used
- In someone with autonomic neuropathy, treat any postural drop as a reason to escalate the dose more slowly
The statistics, in plain English
A risk ratio of 2.45 means hypotension events were about two and a half times as common on tirzepatide as on comparator, but the confidence interval from 1.35 to 4.45 is wide - typical of pooling uncommon events - so the size of the increase is much less certain than its existence. For semaglutide the intervals for both hypertension (0.57 to 1.15) and hypotension (0.81 to 2.36) cross 1.0, meaning the data cannot distinguish its effect from no effect at all; that is an absence of evidence, not proof of safety, since these are adverse event reports rather than measured blood pressures. Reported events also undercount real hypotension, because mild postural symptoms rarely reach a trial adverse event form.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free